Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATORE-CIN trial of atorvastatin reload to prevent contrast-induced nephropathy
PACTR202110707328144Phase 3Completed
- Sponsor
- Hedi Chaker Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of atorvastatin in contrast-induced nephropathy (CIN) and acute kidney failure (AKF) (2 arms), sponsored by Hedi Chaker Hospital. Primary endpoints: Incidence of cystatin C-based contrast-induced nephropathy and Incidence of serum creatinine-based contrast-induced nephropathy. Started Jun 2020; status: completed.
02
Drugs
atorvastatin
03
Conditions
contrast-induced nephropathy (CIN)acute kidney failure (AKF)
Beyond the preview
Go deeper on PACTR202110707328144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202110707328144.